ITG Isotope Garching

ITG Isotope Technologies Garching (ITG) is a core subsidiary of the ITM Isotope Technologies Munich SE group, specializing in the development, production, and global supply of high-quality medical radioisotopes and radiopharmaceuticals. Based in Garching, Germany, the company is a leading producer of no-carrier-added Lutetium-177 (EndolucinBeta), a critical component in targeted radionuclide therapies for various cancers. ITG operates state-of-the-art GMP manufacturing facilities and provides essential diagnostic and therapeutic isotopes, including Actinium-225 and Gallium-68 generators, to the global healthcare market. The company supports a robust internal pipeline of radiopharmaceutical candidates through its parent company, ITM, while serving as a key contract manufacturer for the broader biotech industry. Their work is central to the advancement of precision oncology through theranostic applications.